Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackstone Inc (BX) vs Revvity Inc (RVTY) Price & Performance

Blackstone IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Blackstone Inc vs Revvity Inc — how do they compare? Blackstone Inc trades at $145.3 (market cap $117.44B), while Revvity Inc trades at $115.28 (market cap $12.91B). The key difference: Blackstone Inc is far larger — about 9.1× Revvity Inc's market cap, and Blackstone Inc pays the higher dividend (3.55%). Which is the better fit depends on your goals.

BXRVTY
Market Cap
$117.44B$12.91B
Sector
FinancialsTechnology
52-Week High
$188.68$117.75
52-Week Low
$102.12$82.26
Dividend Yield
3.55%0.24%
Enterprise Value
$15.23B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackstone Inc

Blackstone (BX) trades at $141.67, up 3.31% today, near its consensus price target of $144.00. The stock shows strong bullish technical signals and has consistently beaten earnings estimates in recent quarters. Recent news highlights strategic acquisitions, including a stake in Air Canada's Aeroplan program and a $25.3 billion Australian home loan portfolio purchase from HSBC, signaling aggressive growth and diversification.

Outlook remains positive with robust revenue growth and high profitability, though elevated valuation ratios and overbought RSI levels suggest near-term caution. Key risks include market volatility and integration challenges from recent deals. Analyst consensus is strongly bullish, supporting a favorable long-term view.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackstone Inc

Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.

Read more on BX

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY